ADMA Biologics issued a formal response on March 25 2026 to a short‑seller research report released the day before by Culper Research. The report accused the company of channel stuffing and claimed that its reported revenue growth was a "fiction," estimating that 2025 revenue would have fallen 3% without the alleged channel stuffing.
The short‑seller’s allegations center on the company’s FY2025 revenue of $510.2 million, which included a 51% jump in ASCENIV sales to $363 million. Culper Research argues that the growth was driven by aggressive channel practices that may inflate sales figures. ADMA’s response states that the allegations are based on speculative assertions and unreliable sources, and that the company remains fully compliant with SEC and GAAP requirements.
ADMA’s board and management emphasized that they are reviewing the assertions made in the report and will take appropriate action if any material inaccuracies are identified. The company reiterated its commitment to accurate and timely disclosure of financial results and business operations, and highlighted its ongoing accelerated share‑repurchase program of $125 million as part of a $200 million total buyback plan for 2026.
The market reaction to the short‑seller report was swift. Shares were trading near their 52‑week low following the release, and the short interest in ADMA was reported at 8%. The report’s claims of channel stuffing and revenue manipulation have heightened investor scrutiny and prompted a reassessment of the company’s revenue recognition practices.
ADMA’s financials remain robust. Gross margin stood at 57.39% and net margin at 28.8% as of March 25 2026. The company expects further margin improvement in fiscal 2026 as its product mix shifts toward higher‑margin IVIG products. Management’s confidence in compliance and the company’s strong financial health—reflected in a “GREAT” score from InvestingPro—helps mitigate some of the negative sentiment generated by the short‑seller allegations.
By publicly addressing the allegations, ADMA aims to protect investor confidence, maintain regulatory compliance, and preserve its reputation. The company’s swift response and commitment to transparency signal its readiness to confront and correct any misinformation, which may help stabilize its market perception and support its long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.